Redwire Q3: Book-to-Bill 1.73 and 50% Backlog Growth, But Margin Boost Partly One-Time, Stock at $7
Read source articleWhat happened
Redwire reported Q3 2026 numbers that mixed strong demand signals with a top-line shortfall, as revenue missed expectations while quarterly book-to-bill reached 1.73 and backlog grew over 50% year-over-year. Gross margin expanded to 32%, but management indicated the improvement benefited from a favorable estimate adjustment, so it may not be fully repeatable. The stock has sold off sharply to approximately $7, well below the $9 entry level identified in the prior DeepValue report, prompting the Seeking Alpha author to upgrade to a cautious Buy. However, the investment case still carries significant dilution risk from the $500 million at-the-market equity program and a share count that more than doubled over the past year. The earlier WAIT thesis emphasized that per-share value capture was capped until adjusted EBITDA turned positive and ATM usage proved modest, conditions that remain unmet despite the stronger bookings.
Implication
The sharp price decline to $7 has compressed valuation to roughly 2x 2027 revenue, which is more attractive than the $9 entry in the prior report but still not cheap given negative EBITDA and heavy dilution. The 1.73 book-to-bill and >50% backlog growth indicate that demand for Redwire's defense and space products is accelerating, which could translate into higher revenue visibility if execution holds. However, the 32% gross margin is suspect because a favorable EAC adjustment artificially lifted it; without that one-time benefit, underlying margin is probably closer to the 27-28% range seen earlier in 2026. The revenue miss in Q3 suggests that converting backlog into shipments remains uneven, and the company has yet to prove it can scale production without further estimate resets. Until Redwire demonstrates sustained positive adjusted EBITDA and limits ATM issuance, the stock is likely to remain range-bound, and any rally should be used to reduce risk rather than chase.
Thesis delta
The previous WAIT thesis emphasized that per-share value was capped by dilution until EBITDA turned positive and ATM usage was modest. Q3 results show stronger demand (1.73 book-to-bill, >50% backlog growth) and improved gross margin (32%) but with a revenue miss and a one-time estimate benefit. The sharp sell-off to ~$7 brings the stock below the $9 attractive entry, making risk/reward more favorable, but the dilution overhang from the $500M ATM remains the key offset.
Confidence
Medium